Abstract
Gene therapy has advanced rapidly over the last few decades due to the development of viral and plasmid vectors for gene delivery and strategies for the direct alteration of DNA/RNA species. Gene replacement using modified viral vectors and plasmids has yielded the greatest levels of therapeutic protein expression in muscle to date, however there are issues with immune mediated response to transgene and viral proteins, hindering sustained expression. New efforts have been made to make viral delivery of genes safer and sustainable, these include the development of hybrid vectors and gutted helper dependant vectors. Non-viral methods of gene delivery and repair provide an alternative to viral based methods. Major concerns with nonviral approaches include the effective distribution and integration of therapeutic molecules throughout the muscle. However, a number of methods have been developed to overcome these obstacles. These include electroporation, vascular injection and occlusion, myotoxins promoting muscle regeneration, muscle specific promoters and the use of pharmacological agents to enhance DNA delivery for gene delivery or gene repair. A number of non-viral plasmid based protocols for gene delivery to muscle have reached the clinical trial stage and show great promise. This review discusses recent advances in viral and non-viral based therapies for muscle diseases, the issues faced by these technologies and current efforts to overcome these obstacles.
Keywords: Muscular dystrophy, gene therapy, delivery, skeletal muscle
Current Genomics
Title: Therapeutic DNA Delivery to Skeletal Muscle
Volume: 7 Issue: 3
Author(s): Anita Quigley, Kym Lowes, Andrew J. Kornberg, Mark J. Cook and Robert Kapsa
Affiliation:
Keywords: Muscular dystrophy, gene therapy, delivery, skeletal muscle
Abstract: Gene therapy has advanced rapidly over the last few decades due to the development of viral and plasmid vectors for gene delivery and strategies for the direct alteration of DNA/RNA species. Gene replacement using modified viral vectors and plasmids has yielded the greatest levels of therapeutic protein expression in muscle to date, however there are issues with immune mediated response to transgene and viral proteins, hindering sustained expression. New efforts have been made to make viral delivery of genes safer and sustainable, these include the development of hybrid vectors and gutted helper dependant vectors. Non-viral methods of gene delivery and repair provide an alternative to viral based methods. Major concerns with nonviral approaches include the effective distribution and integration of therapeutic molecules throughout the muscle. However, a number of methods have been developed to overcome these obstacles. These include electroporation, vascular injection and occlusion, myotoxins promoting muscle regeneration, muscle specific promoters and the use of pharmacological agents to enhance DNA delivery for gene delivery or gene repair. A number of non-viral plasmid based protocols for gene delivery to muscle have reached the clinical trial stage and show great promise. This review discusses recent advances in viral and non-viral based therapies for muscle diseases, the issues faced by these technologies and current efforts to overcome these obstacles.
Export Options
About this article
Cite this article as:
Quigley Anita, Lowes Kym, Kornberg J. Andrew, Cook J. Mark and Kapsa Robert, Therapeutic DNA Delivery to Skeletal Muscle, Current Genomics 2006; 7 (3) . https://dx.doi.org/10.2174/138920206777780265
DOI https://dx.doi.org/10.2174/138920206777780265 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Potential Advantages of Using Synchrotron X-ray Based Techniques in Pediatric Research
Current Medicinal Chemistry Recent Advances in Nasal Drug Delivery Using Natural Polymers
Current Drug Therapy Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia
Reviews on Recent Clinical Trials The Canalicular Bile Salt Export Pump BSEP (ABCB11) as a Potential Therapeutic Target
Current Drug Targets The Use of Human Albumin for the Treatment of Ascites in Patients with Liver Cirrhosis: Item of Safety, Facts, Controversies and Perspectives
Current Drug Safety Intravenous Immunoglobulin Preparations and Autoimmune Disorders: Mechanisms of Action
Current Pharmaceutical Biotechnology Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Diabetes Mellitus and SARS-CoV-2 Infection: Pathophysiologic Mechanisms and Implications in Management
Current Diabetes Reviews The Two Faces of Protein Palmitoylation in Islet β-Cell Function: Potential Implications in the Pathophysiology of Islet Metabolic Dysregulation and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Liposomes and Micro/Nanoparticles as Colloidal Carriers for Nasal Drug Delivery
Current Drug Delivery Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Effect of Chronic Melatonin Administration on Several Physiological Parameters from Old Wistar Rats and Samp8 Mice
Current Aging Science On the Role of Endothelial TRPC3 Channels in Endothelial Dysfunction and Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Apoptosis Following Photodynamic Tumor Therapy: Induction, Mechanisms and Detection
Current Pharmaceutical Design The Lung in Sepsis: Guilty or Innocent?
Endocrine, Metabolic & Immune Disorders - Drug Targets AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models
Current Alzheimer Research Devices and Methods for Closed Reduction of Diaphyseal Fracture
Recent Patents on Biomedical Engineering (Discontinued)